Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
HOME > BUSINESS
BUSINESS
- Amgen Astellas BioPharma to Become Amgen’s Wholly Owned Subsidiary; Continue Copromotion with Astellas
January 24, 2020
- Takeda to Liquidate Shire’s Irish Holding Firm
January 23, 2020
- Kissei’s Spinocerebellar Degeneration Drug Fails to Meet Primary Goal in PIII, but Shows Positive Results in Severe Patients
January 23, 2020
- Otsuka Ties Up with UK’s PhoreMost, Initial Focus on Gene Therapy
January 22, 2020
- Towa to Develop Adherence Support Tools with Game Maker, Eyes Launch in FY2021
January 22, 2020
- Pfizer Rolls Out Japan’s Second Rituxan Biosimilar
January 21, 2020
- GSK, NCC Join Hands to Propel Cancer Drug Development, Translational Research
January 21, 2020
- Keytruda Snags Best-Seller Title in 2019 Drug Ranking: Encise
January 20, 2020
- Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist
January 20, 2020
- Forxiga Filed for Chronic Heart Failure in Japan: AstraZeneca
January 20, 2020
- Nichi-Iko Quits Herceptin Biosimilar, Focus Now on Avastin Follow-On
January 20, 2020
- Mitsubishi Tanabe to Be Delisted from TSE on February 27
January 20, 2020
- Astellas to Build New API Facility for Prograf in Toyama
January 20, 2020
- Astellas Completes US$3 Billion Audentes Buyout
January 17, 2020
- Asahi Kasei Closes Veloxis Acquisition
January 16, 2020
- JT Grabs Japan Rights to Dermavant’s Psoriasis/Eczema Drug
January 16, 2020
- Orix to Acquire Majority Stake in Generic Drug Maker Kobayashi Kako
January 16, 2020
- ASKA Bags Japan Rights for Cervical Dysplasia Therapy from Kyoto Univ. Spinoff
January 16, 2020
- Tapped as Next Mitsubishi Tanabe Chief, Hiroaki Ueno Vows to Enrich Pipeline, Accelerate Global Biz
January 15, 2020
- Astellas, Adaptimmune Hook Up on Off-the-Shelf Cell Therapies
January 15, 2020
ページ
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…